Oxford BioMedica PLC

Clinic Roundup.
BIOWORLD Today; 11/3/2009; 1883 words; ...detectable systemic exposure. Data were presented at the Digestive Disease Week conference in Los Angeles. o Oxford BioMedica plc, of Oxford, UK, opened for recruitment a Phase II trial of TroVax in patients with prostate cancer that is unresponsive...

Oxford BioMedica Gets Green Light For TroVax Phase III Trial.
BIOWORLD Today; 11/3/2009; 1248 words; Washington Editor Oxford BioMedica plc is ready to begin a Phase III trial...protocol assessment. The company, of Oxford, UK, plans to start the study in...into what we're doing," Oxford BioMedica CEO Alan Kingsman told BioWorld Today...

British gene therapy specialist Oxford BioMedica Plc (Oxford, UK) said on Thursday patients had responded well to the second dose of its experimental Parkinson's disease drug, ProSavin, news that sent its shares sharply higher.(RESEARCH & TECHNOLOGY)
MondayMorning; 10/19/2009; 728 words; The firm released fresh data from its Phase I/II clinical trials with ProSavin, which had already produced encouraging initial results in July. Thursday's data showed that all patients treated at the second dose level with ProSavin had shown further improvement in motor function after completing a

No. 183 European Oncology Conference A New 'TRIST?' Subset Data Keeping TroVax Hopes Alive.(Conference news)
BIOWORLD Today; 9/23/2009; 1855 words; ...end up reviving excitement in Oxford BioMedica plc's troubled cancer vaccine...Tuesday, sending shares of the Oxford, UK-based firm (LSE:OXB...2008.) The new data from Oxford BioMedica's trial came from those analyses...

BioMedica Shows Good Data in ProSavin Parkinson's Trial.
BioWorld International; 7/15/2009; 994 words; BioWorld International Correspondent LONDON - Oxford BioMedica plc announced encouraging data in the Phase I/II trial...six months post-treatment. John Dawson, CEO of Oxford BioMedica, said that discussions with prospective licensees...